Prediction of cognitive decline in healthy aging based on neuropsychiatric symptoms and PET-biomarkers of Alzheimer's disease.
Aging
Alzheimer’s PET biomarkers
Cognitive decline
Neuropsychiatric symptoms
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
received:
17
10
2023
accepted:
22
11
2023
revised:
21
11
2023
medline:
20
12
2023
pubmed:
20
12
2023
entrez:
20
12
2023
Statut:
aheadofprint
Résumé
Neuropsychiatric symptoms (NPS) have been associated with a risk of accelerated cognitive decline or conversion to dementia of the Alzheimer's Disease (AD) type. Moreover, the NPS were also associated with higher AD biomarkers (brain tau and amyloid burden) even in non-demented patients. But the effect of the relationship between NPS and biomarkers on cognitive decline has not yet been studied. This work aims to assess the relationship between longitudinal cognitive changes and NPS, specifically depression and anxiety, in association with AD biomarkers in healthy middle-aged to older participants. The cohort consisted of 101 healthy participants aged 50-70 years, 66 of whom had neuropsychological assessments of memory, executive functions, and global cognition at a 2-year follow-up. At baseline, NPS were assessed using the Beck Depression and Anxiety Inventories while brain tau and amyloid loads were measured using positron emission topography. For tau burden, THK5351 uptake is used as a proxy of tau and neuroinflammation. Participants, declining or remaining stable at follow-up, were categorized into groups for each cognitive domain. Group classification was investigated using binary logistic regressions based on combined AD biomarkers and the two NPS. The results showed that an association between anxiety and prefrontal amyloid burden significantly classified episodic memory decline, while the classification of global cognitive decline involved temporal and occipital amyloid burden but not NPS. Moreover, depression together with prefrontal and hippocampal tau burden were associated with a decline in memory. The classification of participants based on executive decline was related to depression and mainly prefrontal tau burden. These findings suggest that the combination of NPS and brain biomarkers of AD predicts the occurrence of cognitive decline in aging.
Identifiants
pubmed: 38114820
doi: 10.1007/s00415-023-12131-0
pii: 10.1007/s00415-023-12131-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fédération Wallonie-Bruxelles
ID : 17/21-09 SLEEPDEM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Geda YE, Roberts RO, Knopman DS et al (2008) Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry 65:1193–1198. https://doi.org/10.1001/archpsyc.65.10.1193
doi: 10.1001/archpsyc.65.10.1193
pubmed: 18838636
pmcid: 2575648
Mortby ME, Ismail Z, Anstey KJ (2018) Prevalence estimates of mild behavioral impairment in a population-based sample of pre-dementia states and cognitively healthy older adults. Int Psychogeriatr 30:221–232. https://doi.org/10.1017/S1041610217001909
doi: 10.1017/S1041610217001909
pubmed: 28931446
Geda YE, Smith GE, Knopman DS et al (2004) De novo genesis of neuropsychiatric symptoms in mild cognitive impairment (MCI). Int Psychogeriatr 16:51–60. https://doi.org/10.1017/S1041610204000067
doi: 10.1017/S1041610204000067
pubmed: 15190996
Rosenberg PB, Mielke MM, Appleby BS et al (2013) The association of neuropsychiatric symptoms in MCI with incident dementia and alzheimer disease. Am J Geriatr Psychiatry 21:685–695. https://doi.org/10.1016/j.jagp.2013.01.006
doi: 10.1016/j.jagp.2013.01.006
pubmed: 23567400
Burhanullah MH, Tschanz JT, Peters ME et al (2020) Neuropsychiatric symptoms as risk factors for cognitive decline in clinically normal older adults: the Cache county study. Am J Geriatr Psychiatry 28:64–71. https://doi.org/10.1016/j.jagp.2019.03.023
doi: 10.1016/j.jagp.2019.03.023
pubmed: 31186157
Krell-Roesch J, Syrjanen JA, Machulda MM et al (2021) Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo clinic study of aging. Int J Geriatr Psychiatry 36:1362–1369. https://doi.org/10.1002/gps.5528
doi: 10.1002/gps.5528
pubmed: 33724517
pmcid: 8451750
Panza F, Lozupone M, Bellomo A, Imbimbo BP (2019) Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients? Ageing Res Rev 55:100948. https://doi.org/10.1016/j.arr.2019.100948
doi: 10.1016/j.arr.2019.100948
pubmed: 31454563
Mori T, Shimada H, Shinotoh H et al (2014) Apathy correlates with prefrontal amyloid β deposition in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 85:449–455. https://doi.org/10.1136/jnnp-2013-306110
doi: 10.1136/jnnp-2013-306110
pubmed: 24133289
Bensamoun D, Guignard R, Furst AJ et al (2016) Associations between neuropsychiatric symptoms and cerebral amyloid deposition in cognitively impaired elderly people. J Alzheimers Dis 49:387–398. https://doi.org/10.3233/JAD-150181
doi: 10.3233/JAD-150181
pubmed: 26484900
Krell-Roesch J, Lowe VJ, Neureiter J et al (2018) Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo clinic study of aging. Int Psychogeriatr 30:245–251. https://doi.org/10.1017/S1041610217002368
doi: 10.1017/S1041610217002368
pubmed: 29198244
Brendel M, Pogarell O, Xiong G et al (2015) Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients. Eur J Nucl Med Mol Imaging 42:716–724. https://doi.org/10.1007/s00259-014-2975-4
doi: 10.1007/s00259-014-2975-4
pubmed: 25631614
pmcid: 5849231
Johansson M, Stomrud E, Lindberg O et al (2020) Apathy and anxiety are early markers of Alzheimer’s disease. Neurobiol Aging 85:74–82. https://doi.org/10.1016/j.neurobiolaging.2019.10.008
doi: 10.1016/j.neurobiolaging.2019.10.008
pubmed: 31735378
Yasuno F, Kazui H, Morita N et al (2016) High amyloid-β deposition related to depressive symptoms in older individuals with normal cognition: a pilot study. Int J Geriatr Psychiatry 31:920–928. https://doi.org/10.1002/gps.4409
doi: 10.1002/gps.4409
pubmed: 26766490
Ismail Z, Smith EE, Geda Y et al (2016) Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dementia 12:195–202. https://doi.org/10.1016/j.jalz.2015.05.017
doi: 10.1016/j.jalz.2015.05.017
Ismail Z, Agüera-Ortiz L, Brodaty H et al (2017) The mild behavioral impairment checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations. J Alzheimers Dis 56:929–938. https://doi.org/10.3233/JAD-160979
doi: 10.3233/JAD-160979
pubmed: 28059789
pmcid: 5652315
Lussier FZ, Pascoal TA, Chamoun M et al (2020) Mild behavioral impairment is associated with β-amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. Alzheimers Dementia 16:192–199. https://doi.org/10.1002/alz.12007
doi: 10.1002/alz.12007
Tommasi NS, Gonzalez C, Briggs D et al (2021) Affective symptoms and regional cerebral tau burden in early-stage Alzheimer’s disease. Int J Geriatr Psychiatry 36:1050–1058. https://doi.org/10.1002/gps.5530
doi: 10.1002/gps.5530
pubmed: 33682933
pmcid: 8187284
Babulal GM, Roe CM, Stout SH et al (2021) Depression is associated with tau and not amyloid positron emission tomography in cognitively normal adults. J Alzheimers Dis 74(4):1045–1055
doi: 10.3233/JAD-191078
Yasuno F, Minami H, Hattori H, for the Alzheimer’s Disease Neuroimaging Initiative (2021) Relationship between neuropsychiatric symptoms and Alzheimer’s disease pathology: an in vivo positron emission tomography study. Int J Geriatr Psychiatry 36:598–605. https://doi.org/10.1002/gps.5459
doi: 10.1002/gps.5459
pubmed: 33165946
Tissot C, Therriault J, Pascoal TA et al (2021) Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer’s disease. Alzheimers Dementia Transl Res Clin Interv. https://doi.org/10.1002/trc2.12154
doi: 10.1002/trc2.12154
Jack CR, Knopman DS, Jagust WJ et al (2013) Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207–216. https://doi.org/10.1016/S1474-4422(12)70291-0
doi: 10.1016/S1474-4422(12)70291-0
pubmed: 23332364
pmcid: 3622225
Rizzolo L, Narbutas J, Van Egroo M et al (2021) Relationship between brain AD biomarkers and episodic memory performance in healthy aging. Brain Cogn 148:105680. https://doi.org/10.1016/j.bandc.2020.105680
doi: 10.1016/j.bandc.2020.105680
pubmed: 33418512
Mattis S (1988) Dementia rating scale. Professional manual. Psychological Assessment Resources, Odessa, FL
Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. J Psychiatr Res 12:189–198. https://doi.org/10.1016/0022-3956(75)90026-6
doi: 10.1016/0022-3956(75)90026-6
pubmed: 1202204
Beck AT, Epstein N, Brown G, Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56:893–897. https://doi.org/10.1037/0022-006X.56.6.893
doi: 10.1037/0022-006X.56.6.893
pubmed: 3204199
Beck AT, Steer RA, Carbin MG (1988) Psychometric properties of the Beck depression inventory: twenty-five years of evaluation. Clin Psychol Rev 8:77–100. https://doi.org/10.1016/0272-7358(88)90050-5
doi: 10.1016/0272-7358(88)90050-5
Mouraux C, Van Egroo M, Chylinski D et al (2023) Effort during prolonged wakefulness is associated with performance to attentional and executive tasks but not with cortical excitability in late-middle-aged healthy individuals. Neuropsychology 37:77–92. https://doi.org/10.1037/neu0000868
doi: 10.1037/neu0000868
pubmed: 36355646
Sarazin M, Chauviré V, Gerardin E et al (2010) The amnestic syndrome of hippocampal type in Alzheimer’s disease: an MRI study. JAD 22:285–294. https://doi.org/10.3233/JAD-2010-091150
doi: 10.3233/JAD-2010-091150
pubmed: 20847406
Sánchez-Benavides G, Gómez-Ansón B, Molinuevo JL et al (2010) Medial temporal lobe correlates of memory screening measures in normal aging, MCI, and AD. J Geriatr Psychiatry Neurol 23:100–108. https://doi.org/10.1177/0891988709355271
doi: 10.1177/0891988709355271
pubmed: 20029056
Narbutas J, Van Egroo M, Chylinski D et al (2021) Associations between cognitive complaints, memory performance, mood, and amyloid-β accumulation in healthy amyloid negative late-midlife individuals. J Alzheimers Dis 83:127–141. https://doi.org/10.3233/JAD-210332
doi: 10.3233/JAD-210332
pubmed: 34275899
Klunk WE, Koeppe RA, Price JC et al (2015) The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer’s Dementia 11:1-15.e4. https://doi.org/10.1016/j.jalz.2014.07.003
doi: 10.1016/j.jalz.2014.07.003
pubmed: 25443857
Ishiki A, Harada R, Kai H et al (2018) Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy. Acta Neuropathol Commun 6:53. https://doi.org/10.1186/s40478-018-0556-7
doi: 10.1186/s40478-018-0556-7
pubmed: 29958546
pmcid: 6025736
Rolls ET, Huang C-C, Lin C-P et al (2020) Automated anatomical labelling atlas 3. Neuroimage 206:116189. https://doi.org/10.1016/j.neuroimage.2019.116189
doi: 10.1016/j.neuroimage.2019.116189
pubmed: 31521825
Craik FIM, Salthouse TA (2011) The handbook of aging and cognition, 3rd edn. Psychology Press, New York
doi: 10.4324/9780203837665
Rentz DM, Mormino EC, Papp KV et al (2017) Cognitive resilience in clinical and preclinical Alzheimer’s disease: the association of amyloid and tau burden on cognitive performance. Brain Imaging Behav 11:383–390. https://doi.org/10.1007/s11682-016-9640-4
doi: 10.1007/s11682-016-9640-4
pubmed: 27738998
pmcid: 5391311
Ismail R, Parbo P, Madsen LS et al (2020) The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study. J Neuroinflammation 17:151. https://doi.org/10.1186/s12974-020-01820-6
doi: 10.1186/s12974-020-01820-6
pubmed: 32375809
pmcid: 7203856
Leal SL, Lockhart SN, Maass A et al (2018) Subthreshold amyloid predicts tau deposition in aging. J Neurosci 38:4482–4489. https://doi.org/10.1523/JNEUROSCI.0485-18.2018
doi: 10.1523/JNEUROSCI.0485-18.2018
pubmed: 29686045
pmcid: 5943976
Narbutas J, Chylinski D, Van Egroo M et al (2021) Positive effect of cognitive reserve on episodic memory, executive and attentional functions taking into account amyloid-beta, tau, and apolipoprotein E status. Front Aging Neurosci. https://doi.org/10.3389/fnagi.2021.666181
doi: 10.3389/fnagi.2021.666181
pubmed: 34122044
pmcid: 8194490
Sperling RA, Mormino EC, Schultz AP et al (2019) The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol 85:181–193. https://doi.org/10.1002/ana.25395
doi: 10.1002/ana.25395
pubmed: 30549303
pmcid: 6402593
Dumurgier J, Hanseeuw BJ, Hatling FB et al (2017) Alzheimer’s biomarkers and future decline in cognitive normal older adults. J Alzheimers Dis 60:1451–1459. https://doi.org/10.3233/JAD-170511
doi: 10.3233/JAD-170511
pubmed: 29036824
pmcid: 5773095
Carrillo-Mora P, Luna R, Colín-Barenque L (2014) Amyloid beta: multiple mechanisms of toxicity and only some protective effects? Oxid Med Cell Longev 2014:e795375. https://doi.org/10.1155/2014/795375
doi: 10.1155/2014/795375
Joannette M, Bocti C, Dupont PS et al (2020) Education as a moderator of the relationship between episodic memory and amyloid load in normal aging. J Gerontol Ser A 75:1820–1826. https://doi.org/10.1093/gerona/glz235
doi: 10.1093/gerona/glz235
Banning LCP, Ramakers IHGB, Köhler S et al (2020) The association between biomarkers and neuropsychiatric symptoms across the Alzheimer’s disease spectrum. Am J Geriatr Psychiatry 28:735–744. https://doi.org/10.1016/j.jagp.2020.01.012
doi: 10.1016/j.jagp.2020.01.012
pubmed: 32088096
Peters ME, Lyketsos CG (2015) Beyond memory: a focus on the other neuropsychiatric symptoms of dementia. Am J Geriatr Psychiatry 23:115–118. https://doi.org/10.1016/j.jagp.2014.11.002
doi: 10.1016/j.jagp.2014.11.002
pubmed: 25575934
pmcid: 4293074
Neureiter J, Krell-Roesch J, Pink A et al (2016) Amyloid-β, neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a prospective cohort study (S35.003). Neurology. https://doi.org/10.1212/WNL.86.16_supplement.S35.003
doi: 10.1212/WNL.86.16_supplement.S35.003
Apostolova L, Goukasian N, Do T et al (2016) Effect of brain amyloidosis on the emergence of neuropsychiatric behaviors in MCI over time (I12.012). Neurology 86(Suppl 16):P2.232
doi: 10.1212/WNL.86.16_supplement.P2.232
Martínez NF, Allen IE, Kramer J et al (2021) Neuropsychiatric symptoms in early and late onset Alzheimer’s Disease (2452). Neurology. https://doi.org/10.1212/WNL.96.15_supplement.2452
doi: 10.1212/WNL.96.15_supplement.2452
pubmed: 34556567
Murugan NA, Chiotis K, Rodriguez-Vieitez E et al (2019) Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. Eur J Nucl Med Mol Imaging 46:1369–1382. https://doi.org/10.1007/s00259-019-04305-8
doi: 10.1007/s00259-019-04305-8
pubmed: 30919054
pmcid: 6486902
Harada R, Ishiki A, Kai H et al (2018) Correlations of 18F-THK5351 PET with postmortem burden of tau and astrogliosis in Alzheimer disease. J Nucl Med 59:671–674. https://doi.org/10.2967/jnumed.117.197426
doi: 10.2967/jnumed.117.197426
pubmed: 28864633
Van Egroo M, Chylinski D, Narbutas J et al (2021) Early brainstem [18F]THK5351 uptake is linked to cortical hyperexcitability in healthy aging. JCI Insight 6:e142514. https://doi.org/10.1172/jci.insight.142514
doi: 10.1172/jci.insight.142514
pubmed: 33290274
pmcid: 7934880
D’Amelio M, Rossini PM (2012) Brain excitability and connectivity of neuronal assemblies in Alzheimer’s disease: from animal models to human findings. Prog Neurobiol 99:42–60. https://doi.org/10.1016/j.pneurobio.2012.07.001
doi: 10.1016/j.pneurobio.2012.07.001
pubmed: 22789698